Large variation in radiation therapy fractionation for multiple myeloma in Australia.
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
13
07
2021
accepted:
22
03
2022
pubmed:
24
5
2022
medline:
20
1
2023
entrez:
23
5
2022
Statut:
ppublish
Résumé
To evaluate the patterns of use of different radiation therapy (RT) fractionation for multiple myeloma (MM) bone disease. This is a population-based cohort of patients with MM who had RT between 2012 and 2017 as captured in the statewide Victorian Radiotherapy Minimum Data Set in Australia. Data linkage was performed to identify subsets of RT delivered within 3 months of death. RT fractionation was classified into four groups: single-fraction (SFRT), 2-5, 6-10, and > 10 fractions. Changes in RT fractionation use over time were evaluated with the Cochran-Armitage test for trend. Factors associated with RT fractionation were evaluated using multivariate logistic regressions. Nine hundred and sixty-seven courses of RT were delivered in 623 patients. The proportion of SFRT, 2-5, 6-10 and > 10 fractions RT was 18%, 47%, 28%, and 7%, respectively. There was an increase in the use of 2-5 fractions, from 48% in 2012 to 60% in 2017 (p-trend < .001), with corresponding decrease in the use of 6-10 fractions, from 26% in 2012 to 20% in 2017 (p-trend = .003). Nine percent (40/430) of RT courses at private institutions were SFRT, compared to 25% (135/537) in public institutions (p < .001). In multivariate analyses, treatment in private institution was the strongest predictor of multifraction RT use. SFRT use was more common closer to the end of life-18%, 14%, and 33% of RT within 2-3, 1-2, < 1 month of death, respectively. There is increasing use of shorter course RT (2-5 fractions) for MM over time. SFRT use remains low, with large variation in practice.
Identifiants
pubmed: 35599450
doi: 10.1111/ajco.13783
pmc: PMC10084224
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-157Informations de copyright
© 2022 The Authors. Asia-Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd.
Références
Clin Oncol (R Coll Radiol). 2021 Dec;33(12):e530-e539
pubmed: 34366206
Asia Pac J Clin Oncol. 2023 Feb;19(1):149-157
pubmed: 35599450
Med J Aust. 2021 Mar;214(5):236-237.e1
pubmed: 33610136
J Clin Oncol. 2007 Apr 10;25(11):1423-36
pubmed: 17416863
BMJ. 2003 Jul 26;327(7408):195-8
pubmed: 12881260
Ann Oncol. 2021 Mar;32(3):309-322
pubmed: 33549387
Cancer. 2005 Jan 15;103(2):393-401
pubmed: 15593373
Clin Genitourin Cancer. 2022 Feb;20(1):e7-e15
pubmed: 34366292
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):61-66
pubmed: 31505246
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):56-63
pubmed: 16814955
Lancet Oncol. 2021 Mar;22(3):e119-e130
pubmed: 33545067
J Med Imaging Radiat Oncol. 2022 Aug;66(5):678-687
pubmed: 35106919
Radiother Oncol. 2021 Jan;154:299-305
pubmed: 33217497
Clin Lymphoma Myeloma Leuk. 2019 May;19(5):e238-e246
pubmed: 30904388
Strahlenther Onkol. 2017 Sep;193(9):742-749
pubmed: 28573476
Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1012-1016
pubmed: 30981834
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1452-7
pubmed: 16413695
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):794-808
pubmed: 29976492
J Med Imaging Radiat Oncol. 2022 Mar;66(2):233-241
pubmed: 35243787
Radiother Oncol. 2015 Nov;117(2):386-9
pubmed: 26243679
Am J Hematol. 2022 May;97 Suppl 1:S3-S25
pubmed: 35234302
Lancet Oncol. 2022 Jan;23(1):65-76
pubmed: 34871550